Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Abstract
The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is...
Paper Details
Title
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Published Date
Jan 24, 2019
Volume
380
Issue
4
Pages
347 - 357
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History